Asia-Pacific Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Asia-Pacific Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 119
  • No of Figures: 27

Asia-Pacific Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Primary Angle-Closure Glaucoma Market

Market Analysis and Insights: Asia-Pacific Primary Angle-Closure Glaucoma Market

The primary angle-closure glaucoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.1% in the forecast period of 2021 to 2028 and is expected to reach USD 340.82 million by 2028. Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the key drivers for primary angle-closure glaucoma market.

Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy.

The increasing population of women and greater female to male ratio in angle-closure glaucoma due to various anatomical and hormonal factors showed the prevalence of the disease in women with increasing women population which is expected to drive the primary angle-closure glaucoma market in the forecasted period. The poor reimbursements are seen as a restraint for the primary angle-closure glaucoma market. The governing body for the approval of products has a significant role in the primary angle-closure glaucoma market growth. The increasing approval of the product for the primary angle-closure glaucoma is expected to boost the market in the forecasted period and will act as opportunities for the primary angle-closure glaucoma market growth. The risks associated with the micro-invasive glaucoma surgery acts as a challenge for the primary angle-closure glaucoma market.

The primary angle-closure glaucoma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the primary angle-closure glaucoma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Primary Angle-Closure Glaucoma Market

Primary Angle-Closure Glaucoma Market Scope and Market Size

The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, acute angle-closure glaucoma segment is dominating in the primary angle-closure glaucoma market owing to the high incidence cases for acute cases.
  • On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, diagnosis segment is dominating in the primary angle-closure glaucoma market due to the primary test and secondary testing options available for the diagnosis and physicians after a proper diagnosis only prefer the medical procedure.
  • On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others. In 2021, hospitals segment is dominating the primary angle-closure glaucoma market as this segment is specialized in conducting various surgical interventions and has a large professional’s portfolio available for giving the proper treatment.
  • On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, direct tender segment dominates the primary angle-closure glaucoma market as they are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics.

Primary Angle-Closure Glaucoma Market Country Level Analysis

The primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.

The countries covered in Asia-Pacific primary angle-closure glaucoma market report are the Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific.

Asia-Pacific is expected to grow with the most promising growth rate in the forecast period of 2021 to 2028 with changing lifestyle and growing urbanization. Japan is expected to dominate in the market in the Asia-Pacific as Japan is one of the leading countries in the world with rapidly increasing product usage and diagnosis segment rate with rising awareness regarding primary angle-closure glaucoma.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Incidence in Emerging Market and Rapid Transition from PACG medication to Surgeries are Creating New Opportunities for Players in the Primary Angle-Closure Glaucoma Market

Primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in particular industry with angle-closure glaucoma surgical and diagnosis product sales, impact of advancement in the primary angle-closure glaucoma and changes in regulatory scenarios with their support for the primary angle-closure glaucoma Market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Primary Angle-Closure Glaucoma Market Share Analysis

The primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to primary angle-closure glaucoma market.

The major companies dealing in the primary angle-closure glaucoma market report are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Bausch & Lomb (a subsidiary of Bausch Health Companies Inc.), Alcon Inc., ZEISS International, NOVAEYE MEDICAL, NIDEK CO., LTD, Allergan (a subsidiary of AbbVie Inc.), APPASAMY ASSOCIATES, Aurolab among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the primary angle-closure glaucoma market.

For instance,

  • In June 2020, Johnson & Johnson Vision Care, Inc. has announced to donate to Optometry Cares – The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation. The total amount of USD 0.30 million were donated by the company for the practitioner in their support to provide eye care to the community affected by COVID-19.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the primary angle-closure glaucoma which also provides the benefits for organisations to improve their offerings for primary angle-closure glaucoma market.

Customization Available: Asia-Pacific Primary Angle-Closure Glaucoma Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets availabl e in the report.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

5 REGULATORY FRAMEWORK

6 PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA

7.1.2 INCREASING WOMEN POPULATION

7.1.3 RISE IN GERIATRIC POPULATION

7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE

7.1.5 INCREASED ECONOMIC BURDEN

7.2 RESTRAINTS

7.2.1 HIGH SURGICAL COSTS OF PACG

7.2.2 INADEQUATE REIMBURSEMENT SCENARIO

7.2.3 DELAYED AND MISDIAGNOSIS OF PACG

7.3 OPPORTUNITIES

7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA

7.3.2 RECENT APPROVAL BY GOVERNING BODIES

7.3.3 INCREASING INCIDENCES IN EMERGING MARKET

7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES

7.4 CHALLENGES

7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES

7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE

7.4.3 LIMITED ACCESS TO TREATMENT

8 IMPACT OF COVID-19 ON ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISION BY MANUFACTURERS

8.5 CONCLUSION

9 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET

9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET

10 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE

10.1 OVERVIEW

10.2 DIAGNOSIS

10.2.1 PRIMARY TEST

10.2.1.1 GONIOSCOPY EXAMINATION

10.2.1.2 SLIT-LAMP EXAMINATION

10.2.1.3 AUTOMATIC STATIC PERIMETRY

10.2.2 SECONDARY TEST

10.2.2.1 ULTRASOUND BIOMICROSCOPY

10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)

10.2.2.3 RETINAL OCT

10.2.2.4 FUNDOSCOPY

10.2.2.5 OTHERS

10.3 TREATMENT

10.3.1 SURGICAL IRIDECTOMY

10.3.2 TRABECULECTOMY

10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)

10.3.4 GONIOTOMY

10.3.5 OTHERS

11 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 AMBULATORY SURGICAL CENTERS

11.4 SPECIALTY CLINICS

11.5 OTHERS

12 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY

13.1 ASIA-PACIFIC

13.1.1 JAPAN

13.1.2 CHINA

13.1.3 INDIA

13.1.4 AUSTRALIA

13.1.5 SINGAPORE

13.1.6 SOUTH KOREA

13.1.7 MALAYSIA

13.1.8 THAILAND

13.1.9 INDONESIA

13.1.10 PHILIPPINES

13.1.11 VIETNAM

13.1.12 REST OF ASIA-PACIFIC

14 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT

16 COMPANY PROFILES

16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 ALCON INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 ZEISS INTERNATIONAL

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NOVA EYE MEDICAL LIMITED

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 NIDEK CO., LTD

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 APPASAMY ASSOCIATES

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 AUROLAB

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 BVI

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 LIGHTMED

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 LUNEAU TECHNOLOGY USA

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 MEDISONIC EQUIPMENTS PVT. LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 MICROSURGICAL TECHNOLOGY

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 NEW VISION

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 NEW WORLD MEDICAL, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 OERTLI INSTRUMENTE AG

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 OMNI LENS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENTS

16.2 SIGHT SCIENCES, INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS

TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS

TABLE 3 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 31 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 32 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 33 JAPAN DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 34 JAPAN PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 35 JAPAN SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 36 JAPAN TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 37 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 40 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 41 CHINA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 42 CHINA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 43 CHINA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 44 CHINA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 45 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 48 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 49 INDIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 50 INDIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 51 INDIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 52 INDIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 53 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 56 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 57 AUSTRALIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 58 AUSTRALIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 59 AUSTRALIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 60 AUSTRALIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 61 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 63 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 64 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 65 SINGAPORE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 66 SINGAPORE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 67 SINGAPORE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 68 SINGAPORE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 69 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 71 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 72 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 73 SOUTH KOREA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 74 SOUTH KOREA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 75 SOUTH KOREA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 76 SOUTH KOREA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 77 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 78 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 79 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 80 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 81 MALAYSIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 82 MALAYSIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 83 MALAYSIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 84 MALAYSIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 85 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 86 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 87 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 88 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 89 THAILAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 90 THAILAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 91 THAILAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 92 THAILAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 93 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 97 INDONESIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 98 INDONESIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 99 INDONESIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 100 INDONESIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 101 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 102 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 103 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 104 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 105 PHILIPPINES DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 106 PHILIPPINES PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 107 PHILIPPINES SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 108 PHILIPPINES TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 109 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 110 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 111 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 112 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 113 VIETNAM DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 114 VIETNAM PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 115 VIETNAM SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 116 VIETNAM TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 117 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 118 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 119 REST OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET

FIGURE 16 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020

FIGURE 17 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 18 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 19 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 21 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)

FIGURE 22 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020

FIGURE 25 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 26 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 27 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 29 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 30 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 31 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)

FIGURE 33 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)

FIGURE 34 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)

FIGURE 35 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)

FIGURE 36 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)

FIGURE 37 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Primary Angle-Closure Glaucoma Market size will be worth USD 340.82 million by 2028.
The Asia-Pacific Primary Angle-Closure Glaucoma Market growth rate will be 6.1% by 2028.
The Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the growth drivers of the Asia-Pacific Primary Angle-Closure Glaucoma Market.
The disease type, type, end user and distribution channel are the factors on which the Asia-Pacific Primary Angle-Closure Glaucoma Market research is based.
The major companies in the Asia-Pacific Primary Angle-Closure Glaucoma Market are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Bausch & Lomb (a subsidiary of Bausch Health Companies Inc.), Alcon Inc., ZEISS International, NOVAEYE MEDICAL, NIDEK CO., LTD, Allergan (a subsidiary of AbbVie Inc.), APPASAMY ASSOCIATES, Aurolab.